Apogee Therapeutics (NASDAQ:APGE) Earns Outperform Rating from Wedbush
Wedbush reaffirmed their outperform rating on shares of Apogee Therapeutics (NASDAQ:APGE – Free Report) in a report released on Monday, RTT News reports. Wedbush currently has a $40.00 target price on the stock. Wedbush also issued estimates for Apogee Therapeutics’ Q4 2023 earnings at ($0.44) EPS, FY2023 earnings at ($2.92) EPS, Q2 2024 earnings at […]
More Stories
Short Interest in ANSYS, Inc. (NASDAQ:ANSS) Increases By 40.9%
ANSYS, Inc. (NASDAQ:ANSS – Get Free Report) saw a large increase in short interest in the month of December. As...
Short Interest in Dorman Products, Inc. (NASDAQ:DORM) Increases By 43.0%
Dorman Products, Inc. (NASDAQ:DORM – Get Free Report) was the target of a significant increase in short interest in December....
News from the WHO: Milestone: COVID-19 five years ago https://ift.tt/8RG6HzT December 30, 2024 at 07:00AM
Published on December 30, 2024 at 07:00AM View on website
FVCBankcorp (NASDAQ:FVCB) vs. First Internet Bancorp (NASDAQ:INBK) Head to Head Analysis
FVCBankcorp (NASDAQ:FVCB – Get Free Report) and First Internet Bancorp (NASDAQ:INBK – Get Free Report) are both small-cap finance companies,...
Clearway Energy (NYSE:CWEN) vs. Hallador Energy (NASDAQ:HNRG) Head to Head Analysis
Hallador Energy (NASDAQ:HNRG – Get Free Report) and Clearway Energy (NYSE:CWEN – Get Free Report) are both oils/energy companies, but...
Sunrise Resources (LON:SRES) Shares Down 6.7% – What’s Next?
Sunrise Resources plc (LON:SRES – Get Free Report) shares fell 6.7% during trading on Monday . The company traded as...